SPATA25: A Potential Drug Target Or Biomarker (G128497)

Target Name: SPATA25

NCBI ID: G128497

SPATA25

SPATA25: A Potential Drug Target Or Biomarker

SPATA25 (dJ337O18.8) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SPATA25 is a non-coding RNA molecule that is located on chromosome 18.8 of the human genome. It is a key regulator of gene expression and has been shown to play a role in the development and progression of various diseases.

One of the most promising aspects of SPATA25 is its potential as a drug target. SPATA25 has been shown to be involved in a variety of cellular processes that are relevant to many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

For example, SPATA25 has been shown to be involved in the regulation of cell growth, differentiation, and apoptosis, which are all important processes that are critical for the development and progression of many diseases.

In addition, SPATA25 has also been shown to be involved in the regulation of cell-cell interactions and in the development of tissues and organs, which are important for the development and progression of many diseases.

SPATA25 is also of interest as a biomarker, as it has been shown to be expressed in a variety of tissues and fluids, including blood, saliva, urine, and tissue samples from cancer patients. This makes it a potential candidate for use as a diagnostic or predictive marker for cancer.

In conclusion, SPATA25 is a gene that has the potential to be a drug target or biomarker for the treatment of a variety of diseases. Further research is needed to fully understand its role and potential applications in medicine.

Protein Name: Spermatogenesis Associated 25

Functions: May play a role in spermatogenesis

The "SPATA25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPATA25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets